Literature DB >> 25890455

Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors.

Aimee M Two1, Wiggin Wu1, Richard L Gallo1, Tissa R Hata2.   

Abstract

Rosacea is a chronic inflammatory skin condition that affects approximately 16 million Americans. Four distinct subtypes of rosacea have been recognized, with transient and nontransient facial flushing, telangiectasia, and inflammatory papules and pustules being among the more commonly recognized features. Although the exact pathogenesis of rosacea is unknown, dysregulation of the innate immune system, overgrowth of commensal skin organisms, and aberrant neurovascular signaling may all have a role in promoting the clinical features of rosacea.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cathelicidin; mast cells; matrix metalloproteinases; microbiome; rosacea; serine proteases; transient receptor potential channels; ultraviolet radiation

Mesh:

Year:  2015        PMID: 25890455     DOI: 10.1016/j.jaad.2014.08.028

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  48 in total

Review 1.  Flushing Disorders Associated with Gastrointestinal Symptoms: Part 2, Systemic Miscellaneous Conditions.

Authors:  Vaibhav Rastogi; Devina Singh; Joseph J Mazza; Dipendra Parajuli; Steven H Yale
Journal:  Clin Med Res       Date:  2018-04-12

Review 2.  Ocular surface inflammation impairs structure and function of meibomian gland.

Authors:  Shin Mizoguchi; Hiroki Iwanishi; Reiko Arita; Kumi Shirai; Takayoshi Sumioka; Masahide Kokado; James V Jester; Shizuya Saika
Journal:  Exp Eye Res       Date:  2017-10       Impact factor: 3.467

3.  Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).

Authors:  James Q Del Rosso; Emil Tanghetti; Guy Webster; Linda Stein Gold; Diane Thiboutot; Richard L Gallo
Journal:  J Clin Aesthet Dermatol       Date:  2020-06-01

Review 4.  Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2017-09-01

Review 5.  An update on the treatment of rosacea.

Authors:  Alexis Lara Rivero; Margot Whitfeld
Journal:  Aust Prescr       Date:  2018-02-01

6.  Characterization of the facial microbiome in twins discordant for rosacea.

Authors:  Asifa K Zaidi; Katrina Spaunhurst; Daniel Sprockett; Yolandas Thomason; Margaret W Mann; Pingfu Fu; Christine Ammons; Meg Gerstenblith; Marie S Tuttle; Daniel L Popkin
Journal:  Exp Dermatol       Date:  2018-03       Impact factor: 3.960

7.  Botulinum toxin blocks mast cells and prevents rosacea like inflammation.

Authors:  Jae Eun Choi; Tyler Werbel; Zhenping Wang; Chia Chi Wu; Tony L Yaksh; Anna Di Nardo
Journal:  J Dermatol Sci       Date:  2018-12-28       Impact factor: 4.563

8.  Photodynamic therapy for rosacea in Chinese patients.

Authors:  Lili Fan; Rui Yin; Ting Lan; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-08-15       Impact factor: 3.631

9.  Disseminated extrafacial rosacea with papulonecrotic lesions.

Authors:  Toshio Demitsu; Rieko Tsukahara; Naoka Umemoto; Satoshi Nakamura; Kazutaka Nagashima; Tomoko Yamada; Maki Kakurai; Yoshiaki Tanaka; Akihiro Kakehashi; Toshiko Miyata
Journal:  J Dermatol Case Rep       Date:  2016-12-31

Review 10.  Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.

Authors:  Giuseppe Micali; Peter Arne Gerber; Francesco Lacarrubba; Gregor Schäfer
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.